Clinical Efficacy and Safety of a Laparoscopic Sleeve Gastrectomy in Obese Patients

Conditions

Obesity

Keywords

Laparoscopic sleeve Gastrectomy, Nonalcoholic Fatty Liver, Type 2 Diabetes, Polycystic Ovary Syndrome, Acanthosis nigricans, Hyperuricemia, Hyperinsulinemia, Sleep apnea Syndrome

Brief summary

This study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal BMI were enrolled.

Detailed description

This study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal BMI were enrolled. All patients with obesity underwent LSG. A multidisciplinary team evaluated participants with obesity at baseline, 1, 3, 6, 12, 24, and 36 months after LSG. Anthropometrics, Metabolic indicators, sex hormones, menstruation，glucose-lipid metabolic markers, and hepatic steatosis assessed by FibroScan(CAP value and E value) were measured baseline and postoperative.

Guo J, Tian P, Yu J, Lu G, Mutailipu K, Wen X, Wang X, You H, Zhu C, Lu L, Wang Y, Qu S, Chen H, Zhuang Y, Bu L.

2026-04-24

10.1007/s11695-025-07961-y

Relationship of serum iron and thyroid hormone in obesity and after laparoscopic sleeve gastrectomy.

Wang X, Fang Y, Huang X, Du L, Ren H, Sheng C, Yang P, Huang Y, Qu S.

2024-11-07

10.1186/s12902-024-01753-8

Relationship of Vitamin A and Thyroid Function in Individuals With Obesity and After Laparoscopic Sleeve Gastrectomy

Bingwei Ma, Peng Yang, Jingyang Gao, Lei Du, Chunjun Sheng et al. (8 authors)

Frontiers in Nutrition2022-03-1510 citations

10.3389/fnut.2022.824193

Interventions

PROCEDURELaparoscopic sleeve gastrectomy

bariatric surgery

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1\) age ranged from 16\ 65 years old, 2) BMI over 37.5 kg/m2, or BMI over 32.5 kg/m2 with diabetes which meets the recommended cutoff for bariatric surgery of the Guidelines for surgical treatment of obesity accompanied with or without type 2 diabetes in China. -

Exclusion criteria

* 1\) secondary cause of obesity such as hypothalamic obesity, Cushing syndrome, and hypophysis dysfunction, etc., 2) pregnancy or lactation, 3) contraindications for laparoscopic surgery, such as gastrointestinal diseases of intra-abdominal infection, adhesions, etc., 4) severe heart, liver and kidney dysfunction, 5) organic and systemic diseases intolerant of surgery.

Design outcomes

Primary

Measure	Time frame	Description
Hepatic steatosis	3 years	hepatic steatosis assessed by FibroScan(CAP value and E value)

Secondary

Measure	Time frame	Description
Menstrual cycles	3 years	the total number of menstrual periods in the last year
Waist/hip Ratio	3 years	WHR=Waist Circumference in centimeter/Hip Circumference in centimeter
TT	3 years	total testosterone in nmol/L
FBG	3 years	fasting blood-glucose in mmol/L
PBG	3 years	postprandial blood-glucose in mmol/L
FINS	3 years	fasting serum insulin in mU/L
PINS	3 years	postprandial insulin in mU/L
ALT	3 years	alanine aminotransferase in U/L
AST	3 years	aspartate aminotransferase in U/L
BMI	3 years	BMI=weight(kg)/height(m)\^2
HOMA-IR	3 years	Homeostatic model assessment insulin resistance index=FBG\*FINS/22.5
HbA1c (%)，	3 years	Glycated hemoglobin
SHBG	3 years	sex hormone-binding globulin in nmol/L
FT	3 years	free testosterone (nmol/L)
DHEAS	3 years	Dehydroepiandrosterone Sulfate (ug/dl)
LDL-C	3 years	low-density lipoprotein cholesterol in mmol/L、
HDL-C	3 years	Hight-density lipoprotein cholesterol in mmol/L、
Fertility	3 years	sexual function, fertility
UA	3 years	Uric acid in umol/L

Outcome results

None listed